Patent details

Basic Information

Publication number:

LUC00330

Type:

SPC

SPC Type:

Medical

Basic Patent Number:

EP168163632

Legal Status:

Inactive

Application number:

LUC00330

First applicant's nationality:

Procedural language:

French

Marketing Authorization

Marketing Authorization Number:

EU/1/23/1738

Marketing Authorization Type:

Marketing Authorization Date:

31/10/2023

Marketing Authorization Status:

Accepted

Marketing Authorization Country:

Luxembourg (LU)

Dates

Filing date:

29/02/2024

First Marketing Authorization date:

31/10/2023

Grant date:

04/03/2026

Activation date:

Publication date:

29/02/2024

Lapsed date:

Expiration date:

Renunciation date:

Revocation date:

Annulment date:

Basic SPC Expiration:

31/10/2038

SPC Extension Expiration:

31/10/2038

Rejection date:

Withdrawal date:

Owner

From:

29/02/2024

 

 

Name:

Loxo Oncology, Inc.

Address:

Lilly Corporate Centre Indianapolis, Indiana 46285, United States (US)

Agent

Name:

OFFICE FREYLINGER S.A.

From:

29/02/2024

Address:

Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)

To:

Publication

Bulletin

Bulletin Heading:

SPC1

Bulletin edition number:

2024/04

Publication date:

11/03/2024

Description:

Section C : Published requests for Supplementary Protection Certificates – I1 publication

Annual Fees

Annual Fee Due Date:

31/12/2036

Annual Fee Number:

21

Annual Fee Amount:

410 Euro

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages
29/02/2024	Summary of the product caracteristics	36
29/02/2024	Application Form	3
29/02/2024	Marketing authorization	4
29/02/2024	MA publication	10
29/02/2024	Outgoing Correspondence	1
29/02/2024	Publication	1
04/03/2026	Publication	1
04/03/2026	Certificate	1
04/03/2026	Outgoing Correspondence	1